Pierre Fabre receives EU approval for infantile hemangioma drug

Pierre Fabre Dermatologie Laboratories has been granted European Commission approval for Hemangiol, a groundbreaking new treatment for infantile hemangioma.

An oral solution developed specifically for paediatric use, it is the first and only drug to be approved in Europe for the treatment of proliferating infantile hemangioma requiring systemic treatment.

Developed in partnership with the University of Bordeaux, the therapy has already been approved in the US and has demonstrated in clinical trials its ability to treat this type of tumour, which can result in airway obstruction, vision problems or disfigurement.

Hemangiol will be introduced first in France and Germany, before gradually being rolled out in other European markets subsequently.

Dr Jean-Jacques Voisard, dermatologist and general manager of Pierre Fabre Dermatologie, said: "Every year, thousands of children will be able to benefit from this new paediatric dermatology treatment specially formulated, developed, tested and produced for safe paediatric use."

Earlier this year, the firm announced a new collaboration with Redx Pharma, which will see the companies ally on research in the promising field of onco-dermatology.